Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ).
Pharmaron Beijing Co., Ltd. has scheduled a meeting of its board of directors for April 28, 2026, to review and approve the first quarterly results for the three months ended March 31, 2026. The board will also consider the formal publication of these results, signaling the upcoming disclosure of the company’s early-2026 financial and operational performance to investors and other stakeholders.
The announcement reiterates the current composition of the company’s board, which includes executive, non-executive, employee representative, and independent non-executive directors. This structure highlights the company’s adherence to corporate governance norms, with a diversified board overseeing financial reporting and regulatory compliance as it prepares its latest quarterly update.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$28.10 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a China-based joint stock company listed in Hong Kong that operates in the pharmaceutical and life sciences sector. The company provides research and development services through its subsidiaries, supporting drug discovery and development for global biopharmaceutical clients across multiple stages of the value chain.
Average Trading Volume: 6,434,825
Technical Sentiment Signal: Buy
Current Market Cap: HK$59.24B
For a thorough assessment of 3759 stock, go to TipRanks’ Stock Analysis page.